International Journal of Drug Policy
Volume 21, Issue 5 , Pages 345-346 , September 2010

The risk of using paid plasma

  • Patricia Volkow

      Affiliations

    • Instituto Nacional de Cancerología, Mexico City, Mexico
    • ,
  • Kimberly C. Brouwer

      Affiliations

    • University of California San Diego School of Medicine, Division of Global Public Health, La Jolla, CA, United States
    • ,
  • Richard S. Garfein

      Affiliations

    • University of California San Diego School of Medicine, Division of Global Public Health, La Jolla, CA, United States
    • ,
  • Steffanie A. Strathdee

      Affiliations

    • University of California San Diego School of Medicine, Division of Global Public Health, La Jolla, CA, United States
    • Corresponding Author InformationCorresponding author at: Division of Global Public Health, University of California, San Diego School of Medicine, 9500 Gilman Drive, MC 0622, La Jolla, CA 92093-0622, United States. Tel.: +1 858 822 6468; fax: +1 858 822 4642.

Received 19 May 2010 ,Accepted 21 May 2010.

References 

  1. Centers for Disease Control Prevention (CDC) . Outbreak of hepatitis C associated with intravenous immunoglobulin administration—United States, October 1993–June 1994. MMWR Morbidity and Mortal Weekly Report. 1994;43:505–509
  2. Centers for Disease Control Prevention (CDC) . Hepatitis A among persons with hemophilia who received clotting factor concentrate—United States, September–December 1995. MMWR Morbidity and Mortality Weekly Report. 1996;45:29–32
  3. Chudy M, Budek I, Keller-Stanislawski B, McCaustland KA, Neidhold S, Robertson BH, et al. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. Journal of Medical Virology. 1999;57:91–99
  4. Echevarria JM, Leon P, Domingo CJ, Lopez JA, Elola C, Madurga M, et al. Laboratory diagnosis and molecular epidemiology of an outbreak of hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain. Transfusion. 1996;36:725–730
  5. Farrugia, A. (in this issue). Response to Volkow et al. International Journal of Drug Policy.
  6. Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA, et al. Outbreak of acute hepatitis C following the use of anti-hepatitis C virus—screened intravenous immunoglobulin therapy. Gastroenterology. 1996;110:1120–1126
  7. James RC, Mustard CA. Geographic location of commercial plasma donation clinics in the United States, 1980–1995. American Journal of Public Health. 2004;94:1224–1229
  8. Lefrere JJ, Loiseau P, Martinot-Peignoux M, Mariotti M, Ravera N, Thauvin M, et al. Infection by hepatitis C virus through contaminated intravenous immune globulin: Results of a prospective national inquiry in France. Transfusion. 1996;36:394–397
  9. Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates. Lancet. 1994;343:211–212
  10. Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Annals of Internal Medicine. 1994;120:1–7
  11. Santagostino E, Mannucci PM, Gringeri A, Azzi A, Morfini M, Musso R, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion. 1997;37:517–522
  12. Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion. 1998;38:573–579
  13. Yu MW, Mason BL, Guo ZP, Tankersley DL, Nedjar S, Mitchell FD, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet. 1995;345:1173–1174

PII: S0955-3959(10)00076-9

doi: 10.1016/j.drugpo.2010.05.002

International Journal of Drug Policy
Volume 21, Issue 5 , Pages 345-346 , September 2010

Article Tools